(Bloomberg) -- Shares of Merck KGaA, the German
drugmaker that bought Switzerland's Serono SA this year, rose to
a record, buoyed by a new study on its cancer drug Erbitux and
speculation it may enter Germany's benchmark DAX index.
The stock gained as much as 7.7 percent, reaching the
highest since the family-controlled company first sold shares in
October 1995. It rose 6.06 euros, or 6.1 percent, to 104.87
euros at 10:45 a.m. in Frankfurt.
Read more at Bloomberg Stocks News
drugmaker that bought Switzerland's Serono SA this year, rose to
a record, buoyed by a new study on its cancer drug Erbitux and
speculation it may enter Germany's benchmark DAX index.
The stock gained as much as 7.7 percent, reaching the
highest since the family-controlled company first sold shares in
October 1995. It rose 6.06 euros, or 6.1 percent, to 104.87
euros at 10:45 a.m. in Frankfurt.
Read more at Bloomberg Stocks News
No comments:
Post a Comment